Repligen Lifts 2026 Revenue Outlook To $844 Million-$852 Million, Yet A $41.2 Million Writedown Drives A Quarterly Loss
Adjusted earnings rose to $0.53 a share in the third quarter, while standard accounting shows a $0.68 per-share loss.
Repligen, which makes the filtration, chromatography and analytics products biopharmaceutical companies use to manufacture biologic drugs, raised its 2026 revenue forecast to $844 million to $852 million in an 8-K filed Tuesday. The same report showed a third-quarter net loss of $38.4 million, or $0.68 a share, after a $41.2 million intangible asset impairment.
Sales up, standard earnings under
Third-quarter revenue was $209.3 million, up 11% as reported and 12.5% organic from $188.8 million a year earlier. CEO Olivier Loeillot called it "a record third quarter."
Under standard accounting, the company lost $29.5 million from operations, against $16.8 million of operating income a year earlier. Net income swung to the $38.4 million loss from $14.9 million of profit, and the loss per share compares with $0.26 of earnings in the prior-year quarter.
On the company's adjusted basis, which excludes the impairment among other items, operating income rose to $33.3 million from $26.8 million. Adjusted earnings per share were $0.53, up from $0.46, and adjusted operating margin reached 15.9% from 14.2%.
The BioLife addition and the new guidance
Repligen closed its BioLife Solutions acquisition on October 6. The company says it adds a cell therapy consumables platform with recurring revenue, and Loeillot said integration is progressing well and the company has already acted on a sizable portion of expected operating expense synergies.
Full-year guidance includes BioLife from the closing date. It implies reported growth of 14.5% to 15.5% and organic growth of 12% to 13%, with adjusted earnings per share of $2.05 to $2.09. About 2.5 points of the reported growth come from acquisitions, mainly BioLife, net of the sale of Polymem.
The company also guides to adjusted operating income of $135 million to $139 million.
Cash pile and the nine-month picture
Cash, cash equivalents and marketable securities stood at $863 million at September 30, against $768 million at the end of 2025. For the first nine months, the company booked a $13.7 million loss on the sale of a business, and its net loss was $25.1 million, against a $35.6 million profit a year earlier.
Repligen is scheduled to discuss the results, BioLife integration and the outlook on a call at 8:00 a.m. ET Tuesday.
Adjusted nine-month earnings per share stand at $1.55 against $1.23 a year earlier, while the standard-accounting figure is a loss of $0.44.
Sources
- 8-K Filing — REPLIGEN CORP (RGEN) — SEC EDGAR
- Exhibit rgen-20261027xexx991.htm — REPLIGEN CORP 8-K exhibit — SEC EDGAR